Loading clinical trials...
Loading clinical trials...
A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma
Conditions
Interventions
Elotuzumab
Lenalidomide
+1 more
Locations
1
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Start Date
October 4, 2018
Primary Completion Date
February 18, 2021
Completion Date
November 4, 2021
Last Updated
March 29, 2023
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions